Mitomycin_C_as_an_adjuvant_treatment_to_resected_gastric_cancer._A_10-year_follow-up._Seventy_consecutive_patients_were_entered_in_a_two-arm_randomized_trial_after_surgical_resection_for_locally_advanced_gastric_cancer._In_the_first_arm,_37_patients_were_included_as_a_control_group,_receiving_no_further_treatment_after_surgery._In_the_second_arm,_33_patients_were_treated_with_adjuvant_chemotherapy_consisting_of_mitomycin_C_(MMC),_20_mg/m2_administered_intravenously_once_every_6_weeks_for_four_consecutive_cycles._All_patients_in_both_arms_were_followed_in_the_same_way_for_5_years._At_5_years_23_of_37_patients_in_the_control_arm_and_7_of_33_patients_in_the_treatment_arm_were_dead_because_of_relapse._Actuarial_survival_curve_was_statistically_significant_in_favor_of_patients_given_adjuvant_MMC_(p_less_than_0.001)._After_10_years_follow-up,_31_of_37_patients_in_the_control_arm_and_16_out_of_33_patients_in_the_treatment_arm_were_dead_because_of_relapse,_the_statistical_differences_continuing_in_the_actuarial_survival_curve_in_favor_of_treated_patients_(p_less_than_0.01)._The_best_advantages_of_adjuvant_treatment_were_observed_in_the_T3N0M0_stage._The_most_frequent_relapse_site_was_the_peritoneal_cavity_and_the_relapse_pattern_shows_special_decrease_in_liver_metastases_in_treated_patients._Toxicity_was_acute_and_mild._No_delayed_toxicity_or_second_malignancies_were_observed._These_data_suggest_that_adjuvant_MMC_after_resected_surgery_of_gastric_cancer_is_a_successful_treatment_and_its_effects_are_still_evident_after_10_years_of_follow-up.